Ladna Michael
Internal Medicine, University of California Davis Medical Center, Sacramento, USA.
Cureus. 2025 May 19;17(5):e84429. doi: 10.7759/cureus.84429. eCollection 2025 May.
A male in his late 40s with a past medical history of morbid obesity status post Roux-en-Y gastric bypass in 2004 presented to the emergency department with recurrent hypoglycemia. The hypoglycemic episodes were triggered by preceding hyperglycemia shortly after a meal. Due to the rapid drop in glucose, he often did not have sufficient time to ingest a rapid-acting carbohydrate snack, resulting in the progression of neuroglycopenic symptoms to syncope. His wife would then immediately administer intramuscular glucagon. A thorough workup did not reveal decompensated liver cirrhosis, chronic kidney disease, congestive heart failure, hypothyroidism, adrenal insufficiency, or insulin use. Serum insulin and C-peptide levels were profoundly elevated. A magnetic resonance imaging (MRI) of the abdomen and pelvis showed no pancreatic mass to suggest an insulinoma. He was referred to interventional radiology (IR) for a selective arterial calcium stimulation test (SACST), which showed an insulin ratio >2 in the gastroduodenal and hepatic arteries, consistent with a diagnosis of nesidioblastosis. He was trialed on numerous medications, which included octreotide, acarbose, diazoxide, and verapamil. He did not tolerate the octreotide due to the adverse effect of worsening abdominal pain and elevated serum lipase consistent with an attack of acute on chronic pancreatitis. The remaining medical regimen was ineffective at preventing hypoglycemia. Although evidence is lacking for use in this context, empagliflozin was then added to prevent the hyperglycemic spikes; however, this too proved ineffective at preventing hypoglycemic episodes. He underwent placement of a percutaneous endoscopic gastrostomy tube intended to tightly control his serum glucose via carbohydrate-low, protein-rich enteral feeds to prevent hyperglycemic episodes; however, this too failed due to suboptimal compliance with oral diet. Endocrinologic surgery declined distal pancreatectomy due to high morbidity and mortality risk with questionable benefit. The patient opted to seek a second opinion at another medical center.
一名40多岁男性,有严重肥胖病史,于2004年接受了Roux-en-Y胃旁路手术,因反复低血糖发作就诊于急诊科。低血糖发作由餐后不久出现的高血糖引发。由于血糖迅速下降,他常常没有足够时间摄入快速起效的碳水化合物零食,导致神经低血糖症状进展为晕厥。随后他的妻子会立即注射肌内胰高血糖素。全面检查未发现失代偿期肝硬化、慢性肾病、充血性心力衰竭、甲状腺功能减退、肾上腺功能不全或使用胰岛素的情况。血清胰岛素和C肽水平显著升高。腹部和盆腔的磁共振成像(MRI)未显示胰腺肿块提示胰岛素瘤。他被转诊至介入放射科进行选择性动脉钙刺激试验(SACST),结果显示胃十二指肠动脉和肝动脉的胰岛素比值>2,符合成神经细胞瘤病的诊断。他试用了多种药物,包括奥曲肽、阿卡波糖、二氮嗪和维拉帕米。由于腹痛加重和血清脂肪酶升高的不良反应,符合慢性胰腺炎急性发作,他无法耐受奥曲肽。其余药物治疗方案在预防低血糖方面无效。尽管缺乏在此情况下使用的证据,但随后加用恩格列净以预防高血糖峰值;然而,这在预防低血糖发作方面也被证明无效。他接受了经皮内镜下胃造口管置入术,旨在通过低碳水化合物、高蛋白的肠内营养严格控制血糖以预防高血糖发作;然而,由于口服饮食依从性欠佳,这一方法也失败了。内分泌外科因远端胰腺切除术的高发病率和死亡率风险以及可疑的获益而拒绝手术。患者选择在另一家医疗中心寻求第二种意见。